Literature DB >> 17884443

Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population.

Taku Hamada1, Kazuhiko Kotani, Kokoro Tsuzaki, Yoshiko Sano, Takashi Murata, Masahiko Tabata, Shigeaki Sato, Naoki Sakane.   

Abstract

The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) gene has been reported to predict a lower risk for developing type 2 diabetes mellitus. However, its effect on the lipid profile has been disputable. Among low-density lipoproteins, small dense low-density lipoprotein (sdLDL) particles have been linked to a greater risk for coronary artery disease. The purpose of this study was to investigate the genetic effect of the Pro12Ala polymorphism in the PPARgamma2 gene on the presence of sdLDL in the general Japanese population. In 379 subjects (aged 54 +/- 13 years), body mass index, percentage of body fat, blood pressure, and biochemical profiles were measured. Pro12Ala polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism. The area of sdLDL subfractions (sdLDL4-7) was analyzed by high-resolution polyacrylamide gel electrophoresis. The frequency of the Ala12 allele in PPARgamma2 was 0.04. There was no difference in total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels between genotypes. However, subjects with the X/Ala genotype (Pro/Ala + Ala/Ala) had significantly higher serum triglyceride levels (P = .001) and a larger area of sdLDL4-7 (P = .002) than those with the Pro/Pro genotype. Multiple regression analysis revealed that the Ala12 allele was a significant variable contributing to the variance in the increased area of sdLDL4-7 (P = .040). In conclusion, the Pro12Ala polymorphism in the PPARgamma2 gene was positively associated with an enlarged area of sdLDL4-7. This polymorphism may play a role in the genetic predisposition to increases in sdLDL4-7.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884443     DOI: 10.1016/j.metabol.2007.05.017

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  G Allele of the rs1801282 Polymorphism in PPARγ Gene Confers an Increased Risk of Obesity and Hypercholesterolemia, While T Allele of the rs3856806 Polymorphism Displays a Protective Role Against Dyslipidemia: A Systematic Review and Meta-Analysis.

Authors:  Shujin Li; Chuan He; Haiyan Nie; Qianyin Pang; Ruixia Wang; Zhifu Zeng; Yongyan Song
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  The association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene with the metabolic characteristics in Chinese women with polycystic ovary syndrome.

Authors:  Jiejin Yang; Hao Gong; Wei Liu; Tao Tao
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

3.  Association between PRO12ALA polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in Iranian patients.

Authors:  Azadeh Motavallian; Sasan Andalib; Golnaz Vaseghi; Hamid Mirmohammad-Sadeghi; Masoud Amini
Journal:  Indian J Hum Genet       Date:  2013-04

4.  Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers.

Authors:  Prasad G Kamble; Stefan Gustafsson; Maria J Pereira; Per Lundkvist; Naomi Cook; Lars Lind; Paul W Franks; Tove Fall; Jan W Eriksson; Erik Ingelsson
Journal:  Ups J Med Sci       Date:  2018-01-05       Impact factor: 2.384

5.  Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.

Authors:  Prasad G Kamble; Maria J Pereira; Stefan Gustafsson; Per Lundkvist; Casimiro Castillejo-López; Tove Fall; Erik Ingelsson; Jan W Eriksson
Journal:  Adipocyte       Date:  2018-08-14       Impact factor: 4.534

6.  PPARγ2 polymorphism and human health.

Authors:  Weimin He
Journal:  PPAR Res       Date:  2009-04-16       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.